Skip to content
Peptide research

MGF

Also known as Mechano Growth Factor
Category
Tissue Repair & Recovery
Administration routes
Injectable
Regulatory status
Not FDA-approved

Synthetic MGF is an E-domain fragment associated with an IGF-1 splice variant expressed by stressed muscle, marketed to speed muscle, tendon, and heart repair. The case rests almost entirely on animal and cell studies; a 2014 study found no measurable activity, calling the mechanism into question. There is no human safety data, and as an IGF-1 relative it carries a theoretical cancer risk. Supply is unregulated black-market product of uncertain purity, and it is not an approved drug.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

MGF (Mechano Growth Factor) names an IGF-1 splice variant expressed after mechanical stress; muscle, heart, and brain tissue produce it when stretched, loaded, or injured. The synthetic 24-amino-acid research peptide corresponds to part of that variant's E-domain. Its proposed independent role in activating satellite cells remains disputed.

How it works in the body

Mechano Growth Factor — a splice variant of IGF-1 produced when muscles are mechanically stressed (exercise, injury). Synthetic MGF E-domain peptides have been proposed to activate satellite cells and support repair, but these effects are disputed and their physiological role is unresolved.

Research overview

MGF research covers muscle regeneration, cardiac repair, and neuroprotection, but remains in early stages. In lab and animal studies, MGF activates muscle stem cells, improves heart function after heart attacks (sheep models), and boosts neural stem cell growth in aging mice (Mayo Clinic). However, a significant 2014 study (Fornaro et al.) found no measurable effect of synthetic MGF on muscle cells, creating real controversy in the field. No human clinical trials have been published. The research base is small and largely from a single group (Geoffrey Goldspink, University College London), and independent replication is critically needed before drawing firm conclusions.

Who researches MGF?

Commonly researched by

  • People exploring tissue repair and injury recovery

    Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.

  • People researching cognitive enhancement

    Studied for neuroprotective effects, memory, or cognitive performance.

  • People researching longevity and anti-aging interventions

    Studied for effects on aging pathways, cellular health, or lifespan extension.

Important considerations for

  • Those with Active cancer

    High

    MGF is a splice variant of IGF-1. Growth factor activity may promote tumor proliferation.

  • Those who are pregnant or breastfeeding

    Absolute

    No safety data. Growth factor signaling during fetal development is unpredictable.

Safety & interactions

Do not use if

  • Active cancer

    High

    MGF is a splice variant of IGF-1. Growth factor activity may promote tumor proliferation.

General cautions

  • Pregnancy

    Absolute

    No safety data. Growth factor signaling during fetal development is unpredictable.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(10)

Rated by level of concern

  • No human safety data exists — all evidence is preclinical

    High

    ClinicalTrials.gov search (no MGF studies registered): https://clinicaltrials.gov/search?term=mechano%20growth%20factor

  • Endogenous E-peptide processing has never been confirmed in vivo despite mRNA detection

    Moderate

    PMID 20130113 (Matheny, Endocrinology 2010 minireview); PMID 23125840 (Zabłocka, Front Endocrinol 2012, 'an important cog or a loose screw in the repair machinery?')

  • Major 2014 study found zero biological activity in multiple cell types, questioning the entire MGF hypothesis

    High

    PMID 24253050 (Fornaro, Am J Physiol Endocrinol Metab 2014)

  • Illegal MGF analogs of unknown purity and properties are sold on the black market with potentially serious side effects

    High

    PMID 16244184 (Goldspink, Br J Sports Med 2005, 'its potential for optimising physical training as well as misuse in doping'); PMID 18353722 (Goldspink, Curr Opin Pharmacol 2008, 'Growth factors, muscle function and doping'); WADA Prohibited List S2: https://www.wada-ama.org/en/prohibited-list

  • As an IGF-1 splice variant, theoretical oncogenic risk exists — IGF-1 signaling is implicated in cancer proliferation

    Theoretical

    PMID 30952709 (Alagaratnam, Anticancer Res 2019); PMID 26622556 (Shang, Oncol Lett 2015); PMID 28986701 (He, Biotechnol Lett 2018)

  • MGF peptide may aggregate at physiological pH, making bioavailability and actual dose uncertain

    Theoretical

    PMID 18068377 (Kuznetsova, Protein Expr Purif 2008); PMID 24768406 (Niu, Int J Pharm 2014, microencapsulation for sustained delivery)

  • Injection site reactions (pain, swelling, redness) reported anecdotally

    Low

    No primary source — anecdotal/user-report only; generic to injected peptides

  • Potential hypoglycemia risk given IGF-1 family membership, though not directly documented for MGF

    Theoretical

    PMID 24253050 (Fornaro, Am J Physiol Endocrinol Metab 2014); PMID 20130113 (Matheny, Endocrinology 2010)

  • Long-term effects of exogenous MGF administration are completely unknown

    High

    Absence of registered trials (ClinicalTrials.gov) and absence of any published chronic-exposure MGF study

  • No standardized manufacturing or quality control for commercially available MGF products

    High

    FDA, Certain Bulk Drug Substances for Use in Compounding (general program page, not MGF-specific): https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding

Interaction summary(8)

Rated by direction with this peptide

  • Recombinant human growth hormone (somatropin)

    CautionTheoretical

    GH is an established upstream inducer of muscle MGF/IGF-1Ec splicing in humans and animals, so exogenous MGF used with GH would add to an already-upregulated endogenous IGF axis. The upstream induction is well documented; the consequence of using both is entirely uncharacterized — no human has received MGF, so this is a precaution, not a demonstrated interaction.

    PMID 15308683 (Iida, J Physiol 2004, lit/lit mice); PMID 14565994 (Hameed, J Physiol 2004, elderly men on rhGH + resistance training); PMID 18799338 (Aperghis, Growth Horm IGF Res 2009, healthy young males on rhGH)

  • Recombinant IGF-1 and IGF-1 analogs (mecasermin, IGF-1 LR3)

    CautionTheoretical

    Both agents derive from the same gene product family; additive IGF-axis stimulation from using them together is plausible but has never been characterized, and MGF's own receptor target remains unidentified.

    PMID 20130113 (Matheny, Endocrinology 2010 minireview)

  • Resistance and eccentric exercise (mechanical loading)

    SynergisticLow

    Mechanical loading is the physiological trigger for the MGF splice variant, and the exercise-induced MGF response is blunted in older adults — the stated rationale for pairing MGF with training, though no trial has tested the combination in humans or animals.

    PMID 12562960 (Hameed, J Physiol 2003); PMID 18067523 (Hameed, Scand J Med Sci Sports 2008, young and elderly)

  • Anabolic-androgenic steroids

    CautionTheoretical

    Anabolic steroid administration alters stretch-induced muscle MGF expression in a rat model; no toxicology data exist for using steroids with MGF.

    PMID 24062630 (Ikeda, ScientificWorldJournal 2013); PMID 18353722 (Goldspink, Curr Opin Pharmacol 2008)

  • Active malignancy or history of cancer (including IGF-1R-targeted oncology therapy)

    CautionTheoretical

    MGF/IGF-1Ec is expressed in human tumors and modulates cancer cell proliferation and invasion in vitro with inconsistent direction, so administration alongside or after cancer treatment is an unquantified risk rather than a known one.

    PMID 30952709 (Alagaratnam, Anticancer Res 2019); PMID 26622556 (Shang, Oncol Lett 2015)

  • Insulin and insulin secretagogues (sulfonylureas)

    CautionTheoretical

    Hypoglycemia is a class concern for mature IGF-1, but the MGF E-domain has no demonstrated insulin- or IGF-1-receptor agonism and no glucose-lowering effect has been reported in any species, so this is inherited-class precaution rather than an observed interaction.

    PMID 24253050 (Fornaro, Am J Physiol Endocrinol Metab 2014); PMID 20130113 (Matheny, Endocrinology 2010)

  • Therapeutic ultrasound and other rehab modalities

    CautionTheoretical

    Therapeutic ultrasound decreased MGF mRNA expression after muscle contusion injury in a single rat study. That concerns the endogenous MGF repair response, not exogenous MGF dosing, so any implication for people injecting MGF is inferential.

    PMID 17601477 (McBrier, Arch Phys Med Rehabil 2007)

  • Cisplatin (and other neurotoxic chemotherapy)

    ProtectiveTheoretical

    MGF interacted with nucleolin to protect neurons against cisplatin-induced neurotoxicity in a preclinical model, suggesting a neuroprotective pairing — but the same pro-survival signaling could in principle shield tumor cells, so this is a research finding, not a clinical recommendation.

    PMID 32511954 (Podratz, Exp Neurol 2020)

Known risks(10)

  • No human safety data exists — all evidence is preclinical

  • Endogenous E-peptide processing has never been confirmed in vivo despite mRNA detection

  • Major 2014 study found zero biological activity in multiple cell types, questioning the entire MGF hypothesis

  • Illegal MGF analogs of unknown purity and properties are sold on the black market with potentially serious side effects

  • As an IGF-1 splice variant, theoretical oncogenic risk exists — IGF-1 signaling is implicated in cancer proliferation

  • MGF peptide may aggregate at physiological pH, making bioavailability and actual dose uncertain

  • Injection site reactions (pain, swelling, redness) reported anecdotally

  • Potential hypoglycemia risk given IGF-1 family membership, though not directly documented for MGF

  • Long-term effects of exogenous MGF administration are completely unknown

  • No standardized manufacturing or quality control for commercially available MGF products

Drug interactions(5)

  • Exogenous IGF-1 (Mecasermin/Increlex)

    Additive growth factor signaling. Co-administration could amplify IGF pathway activation and increase hypoglycemia risk. Not studied.

  • Growth Hormone (GH/Somatropin)

    GH stimulates endogenous IGF-1 production. Combined use may lead to unpredictable IGF-1 pathway overstimulation. No clinical data.

  • Insulin

    Both IGF-1 family peptides and insulin lower blood glucose. Theoretical additive hypoglycemia risk with concurrent use.

  • Other IGF-1 splice variants (IGF-1 LR3, DES IGF-1)

    Overlapping growth factor pathways. Using MGF with other IGF-1 variants may produce unpredictable mitogenic effects. No safety data exists.

  • Anti-cancer therapies targeting IGF-1R

    MGF may partially signal through IGF-1R at high concentrations. Could theoretically interfere with IGF-1R-targeted cancer treatments.

Research & benefits

Evidence base

Evidence Level
Preclinical
Total Studies
15
Human Studies
0

All MGF research to date is preclinical, conducted in cell cultures, rodent models, and one sheep cardiac model. No controlled human clinical trials have been conducted. Results are mixed: some labs report robust effects on satellite cell activation and cardiac protection, while a well-powered 2014 study found no significant effects on myoblasts or primary muscle stem cells. The existence of endogenous E-peptide processing in vivo has not been confirmed despite mRNA detection.

Researched for(7)

Rated by confidence in the evidence

  • Satellite cell activation and muscle repair

    Low

    Rodent studies suggest muscle activation signals. Human evidence includes gene-expression studies and experiments in cultured human muscle cells, with contradictory results.

    PMID 12692175 (Hill & Goldspink, J Physiol 2003); PMID 12892408 (Hill & Goldspink, J Anat 2003); PMID 17531227 (Ates, FEBS Lett 2007); contradicted by PMID 24253050 (Fornaro, Am J Physiol Endocrinol Metab 2014)

  • Enhanced myogenic progenitor cell transplantation

    Speculative

    Improved cell engraftment in one mouse transplantation study; not replicated or tested in humans.

    PMID 17845560 (Mills, Am J Transplant 2007)

  • Cardiac protection and post-infarction recovery

    Low

    Multiple rodent heart-attack studies show benefit, with a plausible mechanism, but no human trials.

    PMID 17581790 (Carpenter, Heart Lung Circ 2008); PMID 25678113 (Peña, Biomaterials 2015); PMID 36467694 (Solís, Front Physiol 2022)

  • Anti-apoptotic effects on myocytes

    Low

    Reduced apoptosis in cultured rat cardiac myocytes under stress, not tested in skeletal muscle.

    Doroudian et al. 2014, Biomed Microdevices, PMID 24908137 (in vitro rat cardiomyocytes, hypoxic stress, TUNEL assay)

  • Stem cell recruitment and migration

    Low

    Cell studies report increased stem and progenitor cell migration, including human mesenchymal stem cells in culture; no clinical benefit has been established.

    PMID 24140053 (Wu, BBRC 2013); PMID 26260632 (Luo, Growth Factors 2015); PMID 24434354 (Zhang, Exp Cell Res 2014); PMID 39067248 (Feng, BBRC 2024)

  • Neurogenesis and neuroprotection in aging

    Low

    Consistently neuroprotective across several rodent and cell studies, but no human neuroprotection data exists.

    PMID 16144956 (Dluzniewska, FASEB J 2005); PMID 15120599 (Aperghis, Brain Res 2004); PMID 19735655 (Quesada, Exp Neurol 2009); PMID 21259326 (Quesada, J Neurosci Res 2011); PMID 28683812 (Tang, Mol Brain 2017)

  • Potential sarcopenia countermeasure

    Speculative

    Human data show only a blunted response with aging; no trial has tested MGF itself.

    PMID 12562960 (Hameed, J Physiol 2003); PMID 21354439 (Kandalla, Mech Ageing Dev 2011, human myoblasts in vitro); PMID 22506111 (Goldspink, J Aging Res 2012, review)

Benefits(7)

  • Satellite cell activation and muscle repair

    Kandalla et al. 2011 showed MGF-E peptide increases proliferative lifespan and delays senescence of human satellite cells from neonatal and young adult muscle.

  • Enhanced myogenic progenitor cell transplantation

    Mills et al. 2007 demonstrated that MGF-Ct24E peptide significantly promoted engraftment of human muscle progenitor cells in mice via intramuscular or systemic delivery.

  • Cardiac protection and post-infarction recovery

    Sheep model studies showed intracoronary MGF-24aa-E delivery provided myocardial protection and improved hemodynamic function to a greater extent than mature IGF-1 (reviewed in Zablocka et al. 2012).

  • Anti-apoptotic effects on myocytes

    Doroudian et al. 2014 showed sustained MGF delivery from microrods reduced apoptosis of neonatal rat myocytes under hypoxic stress and increased Bcl-2 expression.

  • Stem cell recruitment and migration

    Doroudian et al. 2014 demonstrated MGF-releasing microrods significantly increased human mesenchymal stem cell migration compared to controls.

  • Neurogenesis and neuroprotection in aging

    Tang et al. 2017 (Mayo Clinic) showed MGF overexpression increased neural progenitor cells, promoted neurogenesis, and preserved olfactory function in aging mice.

  • Potential sarcopenia countermeasure

    Kandalla et al. 2011 found MGF-E peptide enhances satellite cell fusion for muscle repair, proposing it as a strategy to combat age-related sarcopenia.

Key studies(6)

  1. Mechano Growth Factor E peptide activates human muscle progenitor cells and induces an increase in their fusion potential at different ages

    In vitro (human primary cells)Primary cultures from neonatal, young adult, and older adult subjectsN/A (cell culture)

    Kandalla PK, Goldspink G, Butler-Browne G, Mouly V

    Mechanisms of Ageing and Development

    2011

    MGF-E peptide significantly increased proliferative lifespan and delayed senescence of satellite cells from neonatal and young adult muscle, enhanced satellite cell activation, proliferation and fusion. Effect absent in older adult samples.

  2. Mills P, Dominique JC, Lafrenière JF, Bouchentouf M, Tremblay JP

    American Journal of Transplantation

    2007

    MGF-Ct24E peptide improved human muscle progenitor cell transplantation by modulating proliferation and differentiation. Intramuscular or systemic delivery significantly promoted engraftment. Proposed therapeutic agent for Duchenne muscular dystrophy.

  3. Zabłocka B, Goldspink PH, Goldspink G, Górecki DC

    Frontiers in Endocrinology

    2012

    Comprehensive review of MGF biology. MGF acts through non-canonical IGF-1R-independent pathways including MAPK/ERK and PKC/Nrf2. Rapidly induced post-myocardial infarction. Active in cardiac, skeletal muscle, and neural tissues. Emphasized that MGF is highly under-researched.

  4. Mechano growth factor promotes neurogenesis in the aging mouse brain

    In vivo (transgenic mouse model)Transgenic mouse cohortsUp to 24 months follow-up

    Tang JJ, Podratz JL, Lange M, Scrable HJ, Jang MH, Windebank AJ

    Molecular Brain

    2017

    MGF overexpression increased neural progenitor cells in dentate gyrus and SVZ, promoted neurogenesis, and preserved olfactory function in aging mice. Endogenous MGF expression declines with age in neurogenic regions. Early-life induction provided sustained benefits.

  5. Sustained delivery of MGF peptide from microrods attracts stem cells and reduces apoptosis of myocytes

    In vitro / biomaterial studyHuman MSCs, neonatal rat myocytes2-week release period

    Doroudian G, Pinney J, Ayala P, Los T, Desai TA, Russell B

    Biomedical Microdevices

    2014

    MGF encapsulated in PEGDMA microrods released bioactive peptide over 2 weeks. Increased human MSC migration (p<0.05). Reduced myocyte apoptosis under hypoxic stress via increased Bcl-2 expression (p<0.05).

  6. Mechano-growth factor peptide has no apparent effect on myoblasts or primary muscle stem cells

    In vitro (contradictory study)C2C12 cells, primary human myoblasts, primary mouse muscle stem cellsN/A (cell culture)

    Fornaro M, Hinken AC, Needle S, Hu E, Trendelenburg AU, et al.

    American Journal of Physiology - Endocrinology and Metabolism

    2014

    MGF peptide up to 500 ng/mL failed to increase proliferation of C2C12 cells or primary human myoblasts, failed to inhibit differentiation, and showed no activating signaling responses. Directly contradicts previous positive findings.

Regulation & availability

Why researchers look at it

Animal studies show MGF activating dormant muscle stem cells at injury sites and reducing heart attack damage by 35% in sheep — but a well-powered 2014 study found no effect of synthetic MGF on muscle cells, and no human trials exist. If independent work resolves this contradiction, MGF could offer targeted tissue repair without the systemic side effects of growth hormone.

Estimated cost
No approved product and no verified reference price
FDA status
MGF is not FDA-approved and is not eligible for compounding: FDA found that its nomination for the compounding list lacked adequate support (Category 3).
WADA status
Prohibited at all times (in- and out-of-competition). MGF falls under WADA Section S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics. The 2026 WADA Prohibited List explicitly prohibits 'other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching.' MGF is specifically recognized by WADA as a banned substance. Black market MGF analogs designed to evade detection have been confirmed.
Prescribability
No — MGF is not FDA-approved and is not available by prescription.
Availability
MGF is not FDA-approved and is not available by prescription. Neither form has undergone regulatory approval for human therapeutic use in any jurisdiction. Quality and purity of commercially available MGF products are unregulated and variable.

International status

  • EU

    Not approved

  • US

    Not FDA-approved

  • Worldwide

    No regulatory approval in any jurisdiction

Regulatory timeline(8)

  1. 1996
    Geoffrey Goldspink's group first identifies MGF as a mechanically-induced splice variant of IGF-1 in skeletal muscle.
  2. 2007
    Mills et al. publish evidence that synthetic MGF-Ct24E enhances myogenic precursor cell transplantation in mice.
  3. 2011
    Kandalla et al. demonstrate MGF-E peptide activates human satellite cells and increases fusion potential across different ages.
  4. 2012
    Zablocka et al. publish major review highlighting MGF is 'highly under-researched' and raising concerns about illicit use.
  5. 2014
    Fornaro et al. publish contradictory study showing no effect of MGF on myoblasts or primary muscle stem cells, generating significant scientific controversy.
  6. 2014
    Doroudian et al. demonstrate sustained MGF delivery from microrods for cardiac repair applications.
  7. 2017
    Tang et al. (Mayo Clinic) show MGF promotes neurogenesis in aging mouse brain, expanding MGF research beyond muscle.
  8. 2026
    MGF remains on the WADA Prohibited List under Section S2. No published therapeutic human trial identified; IND filing status is not publicly established.

Sources & FAQs

Research sources(8)

Frequently asked questions(5)

What is the difference between MGF and IGF-1?

MGF (IGF-1Ec) is a splice variant of IGF-1 with a unique 24-amino-acid C-terminal peptide. Unlike circulating IGF-1Ea produced by the liver, MGF is expressed locally in tissues after mechanical stress. It acts through different signaling pathways and primarily activates satellite cells for repair rather than promoting general growth.

What is PEG-MGF and how does it differ from regular MGF?

PEG-MGF is MGF with a polyethylene glycol (PEG) molecule attached, which extends its half-life from approximately 5-7 minutes to several hours (estimated 24-72 hours). This allows less frequent dosing and systemic distribution rather than purely local action.

Has MGF been tested in humans?

No controlled clinical trials of MGF have been conducted in humans. All published research is preclinical (cell cultures, rodents, and one sheep cardiac model). The human data that exists comes from studies on endogenous MGF expression patterns, not from administering exogenous MGF peptide.

Why are MGF research results contradictory?

A 2014 study by Fornaro et al. found no effects of MGF peptide on myoblasts or primary muscle stem cells, contradicting earlier positive findings. Possible explanations include differences in peptide preparation, concentration, cell types used, and whether the peptide aggregates at physiological pH. The scientific community has called for independent replication studies.

Is MGF legal?

It is banned by WADA in competitive sports. Using it for performance enhancement or self-administration is not sanctioned by any medical regulatory body.